scholarly journals Detection of ctDNA from dried blood spots after DNA size selection

2019 ◽  
Author(s):  
Katrin Heider ◽  
Jonathan C. M. Wan ◽  
James Hall ◽  
Samantha Boyle ◽  
Irena Hudecova ◽  
...  

AbstractRecent advances in the research and clinical applications of circulating tumour DNA (ctDNA) is limited by practical considerations of sample collection. Whole genome sequencing (WGS) is increasingly used for analysis of ctDNA, identifying copy-number alterations, fragment size patterns, and other genomic features. We hypothesised that low-depth WGS data may be generated from minute amounts of cell-free DNA, and that fragment-size selection may be effective to remove contaminating genomic DNA (gDNA) from small volumes of blood. There are practical advantages to using dried blood spots as these are easier to collect, facilitate serial sampling, and support novel study designs in prospective human studies, animal models and expand the utilisation of archival samples by the removal of gDNA in small volumes. We therefore developed a protocol for the isolation and analysis of cell-free DNA from dried blood spots. Analysing a dried blood spot of 50μL frozen whole blood from a patient with melanoma, we identified ctDNA based on tumour-specific somatic copy-number alterations, and found a fragment size profile similar to that observed in plasma DNA processed by traditional methods. We extended this approach to detect tumour-derived cell-free DNA in a dried blood spot from a mouse xenograft model and were able to identify ctDNA from the originally grafted ascites. Together, our data suggests that ctDNA can be detected and monitored in dried blood spots. This will enable new approaches for sample collection from patients andin vivomodels.

2020 ◽  
Vol 66 (5) ◽  
pp. 697-705 ◽  
Author(s):  
Katrin Heider ◽  
Jonathan C M Wan ◽  
James Hall ◽  
Jelena Belic ◽  
Samantha Boyle ◽  
...  

Abstract Background Recent advances in the study and clinical applications of circulating tumor DNA (ctDNA) are limited by practical considerations of sample collection. Whole-genome sequencing (WGS) is increasingly used for analysis of ctDNA, identifying copy-number alterations and fragmentation patterns. We hypothesized that low-depth/shallow WGS (sWGS) data may be generated from minute amounts of cell-free DNA, and that fragment-size selection may remove contaminating genomic DNA from small blood volumes. Dried blood spots have practical advantages for sample collection, may facilitate serial sampling, and could support novel study designs in humans and animal models. Methods We developed a protocol for the isolation and analysis of cell-free DNA from dried blood spots using filter paper cards and bead-based size selection. DNA extracted and size-selected from dried spots was analyzed using sWGS and polymerase chain reaction (PCR). Results Analyzing a 50 μL dried blood spot from frozen whole blood of a patient with melanoma, we identified ctDNA based on the presence of tumor-specific somatic copy-number alterations, and found a fragment-size profile similar to that observed in plasma DNA. We found alterations in different chromosomes in blood spots from 2 patients with high-grade serous ovarian carcinoma. Extending this approach to serial dried blood spots from mouse xenograft models, we detect tumor-derived cell-free DNA and identified ctDNA from the originally grafted ascites. Conclusion Our data suggest that ctDNA can be detected and monitored in dried blood spots from archived and fresh blood samples, enabling new approaches for sample collection and novel study/trial designs for both patients and in vivo models.


2018 ◽  
Vol 10 (24) ◽  
pp. 2901-2909 ◽  
Author(s):  
Jessica D. Schulz ◽  
Anna Neodo ◽  
Jean T. Coulibaly ◽  
Jennifer Keiser

Ivermectin was quantified in dried blood spot and plasma samples derived fromTrichuris trichiura-infected adults with a validated LC-MS/MS method.


Author(s):  
Steven J. McCann ◽  
Scott Gillingwater ◽  
Brian G. Keevil ◽  
Donald P. Cooper ◽  
Michel R. Morris

Background: Current sampling for total homocysteine (tHcy) is problematic, requiring plasma separation within 15 min. The aim of this study was to develop a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the measurement of tHcy in plasma and dried blood spots and to determine whether the dried blood spot concentration could be used to predict plasma concentrations of tHcy. Methods: LC-MS/MS methodology was optimized to measure tHcy in plasma and dried blood spots. Fifty blood samples collected from heart transplant patients were used to form dried blood spots and for plasma analysis. Plasma tHcy was also measured using the Abbott IMx1 method and values were compared to the tHcy concentrations determined in plasma and dried blood spots using LC-MS/MS methodology. Results: The plasma tHcy LC-MS/MS results compared well with the IMx values: LC-MS/MS=1·18(IMx)-0·44 ( r2=0·915). The within-batch precision ( n =10) of the plasma LC-MS/MS method was < 2·0% at 14·6 and 37·7 µmol/L, respectively; the between-batch precision ( n=10) was 5·0 and 8·0%, respectively, at these concentrations. The method was found to be sensitive down to 1 µmol/L and linear up to at least 100 µmol/L. Dried blood spot LC-MS/MS results were considerably lower than the plasma IMx values ( P < 0·0001): dried blood spot LC-MS/MS=0·33IMx+1·77 ( r2=0·682). The within-batch precision ( n=20) of the dried blood spot LC-MS/MS method was 7·3% and 4·7% at concentrations of 4·0 and 7·9 µmol/L, respectively; the between-batch precision was 12·6% and 7·9% at concentrations of 5·1 and 8·0 µmol/L, respectively. To assess whether dried blood spots are suitable as a screening test to predict plasma tHcy concentrations, arbitary cut-off levels were compared. If it is assumed that a plasma tHcy concentration of >15 µmol/L is raised, a dried blood spot result of >6·8 µmol/L has a sensitivity and specificity in detecting a raised plasma tHcy of 83·3% and 96·2%, respectively, and a positive and negative predictive value of 95% and 86%, respectively, with an efficiency of 90%. Use of a dried blood spot cut-off concentration of 6·2 µmol/L for predicting high plasma tHcy concentrations (above 15 µmol/L) has a sensitivity and specificity of 95·8% and 73·1%, respectively, positive and negative predictive values of 76% and 95%, respectively, and an efficiency of 84%. Conclusions: We have developed a precise and accurate LC-MS/MS method for measuring plasma tHcy concentrations, which uses a small volume of plasma and is suitable for routine use. A satisfactory LC-MS/MS method for the measurement of tHcy in dried blood spots was also developed; this method might be useful in routine screening for raised plasma concentrations of tHcy.


2018 ◽  
Vol 10 (12) ◽  
Author(s):  
Florent Mouliere ◽  
Richard Mair ◽  
Dineika Chandrananda ◽  
Francesco Marass ◽  
Christopher G Smith ◽  
...  

2016 ◽  
Vol 10 (35) ◽  
pp. 1439-1443
Author(s):  
Dagnra Anoumou ◽  
Salou Mounerou ◽  
Ehlan Amivi ◽  
Konou Ahouefa ◽  
Ouro-Medeli Alassane ◽  
...  

2007 ◽  
Vol 14 (11) ◽  
pp. 1522-1525 ◽  
Author(s):  
Rita F. Helfand ◽  
Cesar Cabezas ◽  
Emily Abernathy ◽  
Carlos Castillo-Solorzano ◽  
Ana Cecilia Ortiz ◽  
...  

ABSTRACT Most persons with rubella virus-specific immunoglobulin M (IgM)- or IgG-positive sera tested positive (98% [n = 178] and 99% [n = 221], respectively) using paired filter paper dried blood spot (DBS) samples, provided that DBS indeterminate results were called positive. For persons with IgM- or IgG-negative sera, 97% and 98%, respectively, were negative using DBS.


Sign in / Sign up

Export Citation Format

Share Document